Recent news about Horizon Pharma PLC (HZNP)

Renaissance Investment Management, an investment management company, released its “Midcap Growth Strategy” fourth-quarter investor letter. A copy of the same can be downloaded here. In the fourth quarter, the strategy returned 11.23% (net) compared to a 6.90% return for the Russell Midcap Growth Index. The strategy declined -13.42% (net) in 2022 compared to a -26.72% decline […]

Amgen's (AMGN) key drugs like Prolia, Repatha and Otezla are driving sales. It is also rapidly advancing its robust pipeline.

During these busy times, it pays to stay on top of the latest profit opportunities. And today’s blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company’s fundamental health, I decided to revise my Portfolio Grader recommendations for 121 big blue chips. Chances are that you have at least one of these stocks in your portfolio, so you may want to give this list a skim and act accordingly. This Week’s Ratings Changes

Horizon Therapeutics (HZNP) possesses solid growth attributes, which could help it handily outperform the market.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

DUBLIN, March 16, 2023--Horizon Therapeutics plc (NASDAQ: HZNP):

Amgen Inc. on Thursday said it would lay off about 450 employees, or less than 2% of its workforce, as it faces increasing pressure from drug prices and high inflation.

Sector ETF report for XBI

DUBLIN, March 14, 2023--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of new MRI imaging data from the Phase 3 clinical trial showing UPLIZNA reduced the formation of subclinical (asymptomatic) optic nerve lesions in people with NMOSD. These findings are being presented during the 49th annual meeting of the North American Neuro-Ophthalmology Society (NANOS) March 11-16, 2023, in Orlando, Florida.

Alkermes shares have surged in the past six months, owing to strong sales performance of its new drug Lybalvi and its decision to separate the oncology unit.

When billionaires jump on the same trend, it’s important for investors to take notice. The pieces often don’t come together immediately, but these investors have millions of dollars in resources dedicated to getting the most up-to-date information as quickly as possible. They might see trends months in advance that others might not notice until it’s too late. Hedge fund manager George Soros is a polarizing figure, but you’d be foolish not to take notice of some of his investing trends. The Soros

DUBLIN, March 12, 2023--Horizon Therapeutics announced new data on the use of TEPEZZA (teprotumumab-trbw) in patients with dysthyroid optic neuropathy (DON) at NANOS 2023.

Style Box ETF report for QQQJ

Horizon Therapeutics (HZNP) reports better-than-expected fourth-quarter 2022 results as it beats the Zacks Consensus Estimate for both revenues and earnings.

Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 11.01% and 1.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

While the top- and bottom-line numbers for Horizon Therapeutics (HZNP) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Higher interest rates aren't deterring companies with high credit ratings from borrowing in the U.S. corporate bond market at a record clip in 2023.

If searching out over-$100 stocks to buy seems arbitrary, take a step back and consider this. It’s great to have a mix of stocks in your portfolio. There are all sorts of sizes and flavors of stocks from which to choose, including mega-cap stocks and even small-cap stocks. So it’s understandable that when you’re looking for stocks to buy, you may sometimes miss some obvious well-priced choices that are right in front of you. Some of the best names out there fall into the category of over-$100 st

DUBLIN, February 28, 2023--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that applications for its 2023 #RAREis Global Advocate Grant are open through March 31, 2023. To increase impact and support advocates who are catalysts for rare disease community needs, #RAREis will grant 50 groups with a one-time $5,000 grant. In 2022, the company awarded 30 grants to advocacy organizations.

DUBLIN, March 01, 2023--In accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the "Irish Takeover Rules"), Horizon confirms that, as of the close of business on February 23, 2023, Horizon’s issued ordinary share capital is comprised of 228,832,390 ordinary shares, nominal value $0.0001 per share (the "Ordinary Shares") and 40,000 deferred ordinary shares of €1.00 each. The Company has 384,366 Ordinary Shares which are held as treasury shares. The Ordinary Shar